Document is current
Any future updates will be listed below
-
Authors
Menon, Aravind A.
Gansen, Benedikt
Mulder, Hillary
Neely, Megan L.
Papavasileiou, Panagiotis
Salisbury, Margaret L.
Southern, Brian D.
Hesslinger, Christian
Leonard, Thomas B.
Meissner, Felix
Todd, Jamie L.
-
Funding
Funding for this research was provided by:
The IPF-PRO Registry is supported by Boehringer Ingelheim Pharmaceuticals, Inc. and run in collaboration with the Duke Clinical Research Institute and enrolling centers.
- License Information
-
More Information
Article History
Received: 3 April 2025
Accepted: 29 September 2025
First Online: 22 October 2025
Declarations
:
: The IPF-PRO Registry was approved by the Duke University Institutional Review Board (Pro00046131). The protocol was approved by the relevant Institutional Review Boards and/or local Independent Ethics Committees prior to enrollment at each site (see Acknowledgments). Ethics approval was granted by the Duke Institutional Review Board Protocol Number Pro00082241 to use the biosamples obtained as part of the IPF-PRO Registry for these analyses. All patients provided written informed consent. The IPF-PRO Registry was registered with ClinicalTrials.gov (Identifier: NCT01915511). The MURDOCK Study Community Registry and Biorepository was approved by the Duke University Health Institutional Review Board (Pro00011196) and all participants provided written informed consent. The MURDOCK Study Community Registry and Biorepository was registered with ClinicalTrials.gov (Identifier: NCT01708408).
: Not applicable.
: Aravind Menon reports research support from the Chest Foundation and consulting fees from Kinevant Pharmaceuticals. Benedikt Gansen and Felix Meissner report funding support from Boehringer Ingelheim Pharmaceuticals, Inc for conducting the mass spectrometry analyses for this project. Hillary Mulder, Megan Neely and Jamie Todd are employees of the Duke Clinical Research Institute, which receives funding support from Boehringer Ingelheim Pharmaceuticals, Inc to coordinate the IPF-PRO/ILD-PRO Registry. Jamie Todd also reports research support from AstraZeneca and CareDx and participation on advisory boards for Altavant, Avalyn, Natera, Sanofi and Theravance. Panagiotis Papavasileiou and Christian Hesslinger are employees of Boehringer Ingelheim. Thomas Leonard was formerly an employee of Boehringer Ingelheim Pharmaceuticals, Inc. Margaret Salisbury reports research support from the National Institute of Health; consulting fees from Boehringer Ingelheim, Orinove, Roche; and speaker fees and support for attending meetings from Boehringer Ingelheim. Brian Southern has participated on an advisory board for Boehringer Ingelheim Pharmaceuticals, Inc.
